Jump to content

Idrocilamide

From Wikipedia, the free encyclopedia
(Redirected from Talval)
Idrocilamide
Clinical data
Trade namesTalval, Srilane, Relaxnova, Brolitène
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Topical
ATC code
Identifiers
  • N-(2-Hydroxyethyl)-3-phenyl-2-propenamide, N-(2 hydroxyethyl)cinnamamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.027.414 Edit this at Wikidata
Chemical and physical data
FormulaC11H13NO2
Molar mass191.230 g·mol−1
3D model (JSmol)
  • O=C(\C=C\c1ccccc1)NCCO
  • InChI=1S/C11H13NO2/c13-9-8-12-11(14)7-6-10-4-2-1-3-5-10/h1-7,13H,8-9H2,(H,12,14)/b7-6+ ☒N
  • Key:OSCTXCOERRNGLW-VOTSOKGWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Idrocilamide (trade names Talval, Srilane, Relaxnova, Brolitène[1]) is a medication with skeletal muscle relaxant[2] and anti-inflammatory actions[3] used as a topical cream to treat lumbago and other kinds of muscular pain;[4] it is available on prescription or over-the-counter[citation needed] in France and various other countries.[1]

Interactions

[edit]

Idrocilamide has been reported to be a potent inhibitor of the metabolism of caffeine.[5][6]

References

[edit]
  1. ^ a b Drugs.com: International Drug Names
  2. ^ Bouron A, Rivet M, Nasri-Sebdani M, Guillemain J, Durbin P, Guerrier D, Raymond G (1990). "The direct depressant effect of LCB29 (idrocilamide) on mechanical tension of rat soleus muscle fibers". Canadian Journal of Physiology and Pharmacology. 68 (12): 1503–1509. doi:10.1139/y90-228. PMID 2085796.
  3. ^ Bannwarth B, Le Huec JC, Vinçon G, Labat L, Demotes-Mainard F, Rivaille F, Le Rebeller A (1993). "[Tissue and systemic diffusion of idrocilamide after cutaneous administration]". Revue du Rhumatisme (in French). 60 (12): 932–6. PMID 8012322.
  4. ^ Stehman M, Lehert P (1990). "Clinical double-blind study with idrocilamide ointment in the treatment of acute lumbago". Acta Belgica. Medica Physica. 13 (1): 29–32. PMID 2140002.
  5. ^ Carrillo JA, Benitez J (2000). "Clinically significant pharmacokinetic interactions between dietary caffeine and medications". Clinical Pharmacokinetics. 39 (2): 127–53. doi:10.2165/00003088-200039020-00004. PMID 10976659.
  6. ^ Brazier JL, Descotes J, Lery N, Ollagnier M, Evreux JC (1980). "Inhibition by idrocilamide of the disposition of caffeine". European Journal of Clinical Pharmacology. 17 (1): 37–43. doi:10.1007/bf00561675. PMID 7371698.